Sarepta surges 28% on siRNA trial data for muscular dystrophy
Positive Phase 1/2 results for SRP-1001 and SRP-1003 programs validate pipeline expansion beyond gene therapy
Sarepta Therapeutics shares surged 28% on Tuesday after the company reported positive Phase 1/2 data for its siRNA programs targeting muscular dystrophy, validating its expansion beyond gene therapy into RNA interference treatments.
The Cambridge, Massachusetts-based biotechnology company said preliminary results from SRP-1001, designed to treat facioscapulohumeral muscular dystrophy type 1 (FSHD1), and SRP-1003, targeting myotonic dystrophy type 1 (DM1), demonstrated dose-dependent muscle exposure and early biomarker effects with favorable tolerability. The data revealed no dose-limiting toxicities across tested doses, according to the company announcement.
Chief Executive Officer Doug Ingram said the results show "multiples greater construct into muscle than other approaches," highlighting the platform's potential to deliver RNA therapeutics more effectively to muscle tissue than existing technologies.
The rally marks a significant rebound for a stock that has struggled in recent months. Sarepta's shares have fallen more than 70% from their 52-week high of $76.26, touched earlier this year, as investors questioned the company's growth trajectory following its flagship gene therapy approval for Duchenne muscular dystrophy. The stock closed Tuesday at $22.51, giving the company a market valuation of $1.75 billion.
Analyst sentiment remains divided despite the positive data. Oppenheimer maintained an outperform rating with a $37 price target, suggesting significant upside potential from current levels. However, the consensus analyst target stands at $20.61, below the current share price, reflecting broader concerns about valuation and execution risk. Of 25 analysts covering the stock, 7 rate it a buy, 13 recommend hold, and 5 advise sell or strong sell, according to market data.
The siRNA programs represent a strategic diversification for Sarepta, which built its reputation on gene therapy treatments for rare neuromuscular diseases. Small interfering RNA, or siRNA, works by silencing disease-causing genes at the RNA level, offering a potentially less invasive alternative to gene replacement therapy. The technology could complement Sarepta's existing portfolio and provide additional treatment options for patients with different forms of muscular dystrophy.
FSHD1 affects approximately 1 in 8,000 people worldwide, while DM1 is a rarer condition with an estimated incidence of 1 in 100,000. Both diseases currently lack approved disease-modifying treatments, representing significant commercial opportunities if Sarepta's programs advance successfully through clinical development.
The company reported $2.2 billion in trailing 12-month revenue, though it continues to operate at a loss with negative earnings per share of $7.13. The favorable safety profile demonstrated in the Phase 1/2 studies de-risks the programs' advancement to larger trials, potentially easing concerns about clinical development costs that have weighed on the company's profitability.
Tuesday's surge brought Sarepta's year-to-date performance into positive territory, though the stock remains well below levels seen in early 2025. Institutional investors hold 90.2% of shares, indicating strong institutional ownership that could support the stock if additional positive data materializes.
Investors will be watching for updates on dosing schedules and timing for Phase 2 trials as Sarepta advances the siRNA platform. The company's ability to demonstrate clinical benefit beyond biomarker changes in later-stage studies will be critical to sustaining the momentum from Tuesday's rally and convincing skeptical analysts of the programs' commercial potential.